Cargando…

Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом

BACKGROUND: BACKGROUND: Timely referral of patients for genetic testing to rule out MEN1-associated primary PHPT is important factor in determining treatment strategy and prognosis. In the context of the limited availability of genetic testing, the search for clinical markers indicative of MEN1 gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Мокрышева, Н. Г., Еремкина, А. К., Милютина, А. П., Салимханов, Р. Х., Абойшева, Е. А., Бибик, Е. Е., Горбачева, А. М., Елфимова, А. Р., Ковалева, Е. В., Попов, С. В., Мельниченко, Г. А.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrinology Research Centre 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680550/
https://www.ncbi.nlm.nih.gov/pubmed/37968947
http://dx.doi.org/10.14341/probl13322
_version_ 1785142404712497152
author Мокрышева, Н. Г.
Еремкина, А. К.
Милютина, А. П.
Салимханов, Р. Х.
Абойшева, Е. А.
Бибик, Е. Е.
Горбачева, А. М.
Елфимова, А. Р.
Ковалева, Е. В.
Попов, С. В.
Мельниченко, Г. А.
author_facet Мокрышева, Н. Г.
Еремкина, А. К.
Милютина, А. П.
Салимханов, Р. Х.
Абойшева, Е. А.
Бибик, Е. Е.
Горбачева, А. М.
Елфимова, А. Р.
Ковалева, Е. В.
Попов, С. В.
Мельниченко, Г. А.
author_sort Мокрышева, Н. Г.
collection PubMed
description BACKGROUND: BACKGROUND: Timely referral of patients for genetic testing to rule out MEN1-associated primary PHPT is important factor in determining treatment strategy and prognosis. In the context of the limited availability of genetic testing, the search for clinical markers indicative of MEN1 gene mutations remains an extremely relevant task. AIM: AIM: To determine the diagnostic value of clinical features of primary PHPT in young patients for predicting the presence of MEN1 gene mutations. MATERIALS AND METHODS: MATERIALS AND METHODS: A single-center, prospective study was conducted at the Endocrinology Research Centre, involving 273 patients with PHPT in the period 2015–2022. Based on the results of genetic and laboratory tests, patients were divided into three groups: those with MEN1 gene mutations (MEN+ group, n=71), those without MEN1 gene mutations — isolated sporadic PHPT (MEN- group, n=158), and patients with PHPT and associated endocrine gland disorders — MEN-1 syndrome phenocopies (PHEN group, n=32). Subgroups of patients younger than 40 years of age were also identified. Comparative analysis was performed among the independent groups and subgroups, and logistic regression analysis was used to develop a mathematical model for predicting the probability of the presence of MEN1 gene mutation. RESULTS: RESULTS: Patients in the MEN+ and MEN- groups were comparable by gender and age at manifestation, as well as calcium-phosphorus metabolism parameters and PHPT complications. In the PHEN group, PHPT manifested at older age compared to the other groups (p<0.001 for all), with lower total calcium levels and a trend toward lower iPTH concentrations. The MEN+ group had a significantly higher frequency of multiglandular parathyroid (PG) involvement, PHPT recurrence, and positive family history compared to the MEN- and PHEN groups. Histologically, adenomas predominated in the PHEN and MEN- groups (92% and 94%, respectively), whereas hyperplasia of PGs were more common in the MEN+ group (49%). None of the PHEN patients had all three «classic» components of the MEN-1 syndrome, and the clinical course of PHPT was similar to that of the MEN- group. These differences were also observed in the subgroups of patients younger than 40 years, which formed the basis for the development of a mathematical model. The logistic regression equation for predicting the probability of the presence of the MEN1 gene mutation included eight predictors, with a diagnostic sensitivity of 96% and specificity of 98%. CONCLUSION: CONCLUSION: Based on the analysis performed, eight hereditary predictors of PHPT within the MEN-1 syndrome were identified. A mathematical model was developed to predict the presence of the MEN1 gene mutation in patients, which demonstrated high classification performance on the training dataset. Further refinement of the model will help improve the quality of medical care for patients with PHPT.
format Online
Article
Text
id pubmed-10680550
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Endocrinology Research Centre
record_format MEDLINE/PubMed
spelling pubmed-106805502023-11-10 Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом Мокрышева, Н. Г. Еремкина, А. К. Милютина, А. П. Салимханов, Р. Х. Абойшева, Е. А. Бибик, Е. Е. Горбачева, А. М. Елфимова, А. Р. Ковалева, Е. В. Попов, С. В. Мельниченко, Г. А. Probl Endokrinol (Mosk) Research Article BACKGROUND: BACKGROUND: Timely referral of patients for genetic testing to rule out MEN1-associated primary PHPT is important factor in determining treatment strategy and prognosis. In the context of the limited availability of genetic testing, the search for clinical markers indicative of MEN1 gene mutations remains an extremely relevant task. AIM: AIM: To determine the diagnostic value of clinical features of primary PHPT in young patients for predicting the presence of MEN1 gene mutations. MATERIALS AND METHODS: MATERIALS AND METHODS: A single-center, prospective study was conducted at the Endocrinology Research Centre, involving 273 patients with PHPT in the period 2015–2022. Based on the results of genetic and laboratory tests, patients were divided into three groups: those with MEN1 gene mutations (MEN+ group, n=71), those without MEN1 gene mutations — isolated sporadic PHPT (MEN- group, n=158), and patients with PHPT and associated endocrine gland disorders — MEN-1 syndrome phenocopies (PHEN group, n=32). Subgroups of patients younger than 40 years of age were also identified. Comparative analysis was performed among the independent groups and subgroups, and logistic regression analysis was used to develop a mathematical model for predicting the probability of the presence of MEN1 gene mutation. RESULTS: RESULTS: Patients in the MEN+ and MEN- groups were comparable by gender and age at manifestation, as well as calcium-phosphorus metabolism parameters and PHPT complications. In the PHEN group, PHPT manifested at older age compared to the other groups (p<0.001 for all), with lower total calcium levels and a trend toward lower iPTH concentrations. The MEN+ group had a significantly higher frequency of multiglandular parathyroid (PG) involvement, PHPT recurrence, and positive family history compared to the MEN- and PHEN groups. Histologically, adenomas predominated in the PHEN and MEN- groups (92% and 94%, respectively), whereas hyperplasia of PGs were more common in the MEN+ group (49%). None of the PHEN patients had all three «classic» components of the MEN-1 syndrome, and the clinical course of PHPT was similar to that of the MEN- group. These differences were also observed in the subgroups of patients younger than 40 years, which formed the basis for the development of a mathematical model. The logistic regression equation for predicting the probability of the presence of the MEN1 gene mutation included eight predictors, with a diagnostic sensitivity of 96% and specificity of 98%. CONCLUSION: CONCLUSION: Based on the analysis performed, eight hereditary predictors of PHPT within the MEN-1 syndrome were identified. A mathematical model was developed to predict the presence of the MEN1 gene mutation in patients, which demonstrated high classification performance on the training dataset. Further refinement of the model will help improve the quality of medical care for patients with PHPT. Endocrinology Research Centre 2023-11-10 /pmc/articles/PMC10680550/ /pubmed/37968947 http://dx.doi.org/10.14341/probl13322 Text en Copyright © Endocrinology Research Centre, 2023 https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 License.
spellingShingle Research Article
Мокрышева, Н. Г.
Еремкина, А. К.
Милютина, А. П.
Салимханов, Р. Х.
Абойшева, Е. А.
Бибик, Е. Е.
Горбачева, А. М.
Елфимова, А. Р.
Ковалева, Е. В.
Попов, С. В.
Мельниченко, Г. А.
Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
title Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
title_full Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
title_fullStr Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
title_full_unstemmed Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
title_short Прогнозирование наличия мутации в гене <i>MEN1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
title_sort прогнозирование наличия мутации в гене <i>men1</i> на основании клинического фенотипа пациентов с первичным гиперпаратиреозом
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680550/
https://www.ncbi.nlm.nih.gov/pubmed/37968947
http://dx.doi.org/10.14341/probl13322
work_keys_str_mv AT mokryševang prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT eremkinaak prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT milûtinaap prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT salimhanovrh prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT abojševaea prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT bibikee prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT gorbačevaam prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT elfimovaar prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT kovalevaev prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT popovsv prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom
AT melʹničenkoga prognozirovanienaličiâmutaciivgeneimen1inaosnovaniikliničeskogofenotipapacientovspervičnymgiperparatireozom